Longeveron (LGVN) Income from Continuing Operations (2020 - 2026)
Longeveron's (LGVN) quarterly Income from Continuing Operations came in at 5545000.0 in Q1 2026, up 14.64% year-on-year from 4836890.02 in Q1 2025, and up 11.31% quarter-over-quarter from 6252000.0 in Q4 2025.
Longeveron (LGVN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Longeveron's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 5545000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 14.64% year-over-year to 5545000.0 in Q1 2026; TTM through Mar 2026 was 27384000.0, a 35.82% decrease from a year earlier, with the FY2025 full-year figure at 24340000.0, up 29.52% from the prior year.
- Income from Continuing Operations improved to 5545000.0 in Q1 2026 per LGVN's latest filing, from 6252000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3547000.0 in Q2 2024 and bottomed at 42716000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 5411000.0 (2022), against an average of 7708294.12.
- Across the five-year window, Income from Continuing Operations plunged 942.87% in 2023 and soared 89.9% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 5229000.0 in 2022, then slipped by 4.63% to 5471000.0 in 2023, then increased by 4.11% to 5246000.0 in 2024, then declined by 19.18% to 6252000.0 in 2025, then rose by 11.31% to 5545000.0 in 2026.
- Per Business Quant, the three latest LGVN Income from Continuing Operations figures stand at 5545000.0 (Q1 2026), 6252000.0 (Q4 2025), and 8778000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | -5.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Sep 30, 2025 | -8.78 Mn |
| Jun 30, 2025 | -6.81 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -5.25 Mn |
| Sep 30, 2024 | -4.87 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -4.31 Mn |
| Dec 31, 2023 | -5.47 Mn |
| Sep 30, 2023 | -5.39 Mn |
| Jun 30, 2023 | -5.95 Mn |
| Mar 31, 2023 | -42.72 Mn |
| Dec 31, 2022 | -5.23 Mn |
| Sep 30, 2022 | -5.41 Mn |
| Jun 30, 2022 | -4.92 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | 44.90 Mn |
| Sep 30, 2021 | -22.91 Mn |
| Jun 30, 2021 | -20.06 Mn |